Clinical Trial for Near Infrared Endoventricular Illumination for Neuroprotection in Very Early Cases of Parkinson's Disease (Ev-NIRT) (Ev-NIRT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04261569|
Recruitment Status : Recruiting
First Posted : February 10, 2020
Last Update Posted : May 18, 2022
Parkinson's disease has only pharmacological (essentially dopaminergic) and surgical treatment (essentially high-frequency deep brain stimulation), that are symptomatically effective. none of them is curative, and has the ability to slow down the disease and to protect dopaminergic neurons from death by neurodegeneration. Experimental results, based on preclinical studies, suggest that brain illumination in the Near-InfraRed (NIR) range is likely to slow down this neurodegenerative process.
Thus, a medical device system (called Ev-NIRT) has been developed for 670 nm intracerebral illumination of the substantia nigra pars compacta (SNpc), and is planned to be tested for the treatment of Parkinson's disease.
In this pilot study the investigators will evaluate the feasibility and tolerance of surgery and brain illumination thanks to the Ev-NIRT medical device, in a group of 7 de novo Parkinson's patients implanted with the innovative medical device. Patients will be monitored for 4 years.
|Condition or disease||Intervention/treatment||Phase|
|Very Early Stage of Parkinson's Disease||Device: Ev-NIRT||Not Applicable|
The level of neuroprotection induced by illumination at 670nm appears effective in preclinical studies, and justify the transfer into a clinical trial. The investigators currently have developed and produced implantable devices, to be implanted into the brain through a minimally invasive endoventricular route. The electrical energy required is supplied by the batteries adapted from those used for deep brain stimulation.
The feasibility of trans ventricular implantation is ensured by the experience gained by our team in the endoventricular stimulation of the posterior hypothalamus in the cluster headache.
In this clinical study, the investigators will evaluate the tolerance and safety of intraventricular surgical technic and illumination by the Ev-NIRT medical device implanted into the brain of 7 patients with Parkinson's disease. idiopathic, aged 25-65 years, at a very early stage (less than 2 years of evolution). The NIR illumination will begin immediately after surgery.
The investigators will also evaluate secondarily, the neuroprotective effect of this new treatment modality, by comparing the decrease of dopaminergic neurons by Positron Emission Tomography (PET)-scan using [11C]PE2I) tracer of implanted patients to that of a control group of 7 patients whose characteristics in terms of duration of evolution and clinical severity are identical, but who are not implanted, and therefore not exposed to NIR illumination.
The PET-scan-PE2I exam is conducted in both groups annually for 4 years (a total of 5 measurements) and compared to the PE2I PET obtained at the beginning of participation in the study. A group-wide comparison will be made between the NIR group and the control group.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||14 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||One control arm : patients without any medical device One illuminated arm : patients with intraventricular near-infrared light illumination|
|Masking:||None (Open Label)|
|Official Title:||Clinical Trial for Near Infrared Endoventricular Illumination for Neuroprotection in Very Early Cases of Parkinson's Disease (Ev-NIRT)|
|Actual Study Start Date :||December 14, 2020|
|Estimated Primary Completion Date :||January 2023|
|Estimated Study Completion Date :||May 2026|
Experimental: Illuminated arm
patients with intraventricular near-infrared light illumination
Endoventricular near infra red treatment : Intraventricular pulsed, chronic, cyclic, near-infrared illumination of the Central Nervous System (CNS) at 150 Hz, 15 mW, 1 minute ON and 5 minutes OFF
No Intervention: control arm
patients without any medical device
- Incidence of Ev-NIRT Treatment on Emergent Adverse Events (Tolerance) after surgical intervention and NIR illumination following the implantation of the Ev-NIRT medical device [ Time Frame: 4 years ]Emergent Adverse Events [Safety and Tolerability]
- Characterization of annual neuronal loss observed by decrease in tracer fixation at the striatum level [ Time Frame: 4 years ]Annual measurement of dopaminergic denervation in Positron Emission Tomography (PET) using [11C]PE2I tracer fixation at the striatum level in percentage compared to the white matter fixation of the cerebellum
- Evaluation of the motor clinical signs progression [ Time Frame: 4 years ]Scores on the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS scale sections II, III and IV) [0-100% : higher scores mean worse outcome]
- Evaluation of the non-motor bahavioral signs progression [ Time Frame: 4 years ]Scores on the non-motor scales Behavioral Evaluation in Parkinson's disease (ECMP) [0-4 : higher scores mean worse outcome]
- Evaluation of the non-motor clinical signs progression [ Time Frame: 4 years ]Scores on the non-motor scales Lille Apathy Rating Scale (LARS) [-4/+4 : higher scores mean worse outcome]
- Evaluation of depression signs progression [ Time Frame: 4 years ]Scores on the non-motor scales Beck Depression Inventory (BDI-II) [0-3 : higher scores mean worse outcome]
- Evaluation of the non-motor symptoms signs progression [ Time Frame: 4 years ]Scores on the non-motor scales Non Motor Symptoms scale (NMS) [0-30 : higher scores mean better outcome]
- Comparison between the date of diagnosis and the date of introduction of substitution therapy with dopaminergic drugs or dopamine agonists [ Time Frame: 4 years ]Time period between the date of diagnosis and the date of introduction of dopaminergic substitute therapy or dopaminergic agonists
- Evolution of this prescription of substitution therapy over the duration of study [ Time Frame: 4 years ]Follow up of dosage of dopaminergic substitute therapy or dopaminergic agonists
- Assessment in both groups of the time it takes for the onset of different motor symptoms (including tremor, akinesia and stiffness, speech, walking and balance disorders) and not motor symptoms of Parkinson's disease in relation to initial diagnosis. [ Time Frame: 4 years ]Time period between the date of diagnosis and the date of onset of different motor and non-motor symptoms objectified by an increase in item scores specific to these symptoms on the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS scale) passed into OFF drug [0-100% : higher scores mean worse outcome]
- Evolution of the quality of life of patients in both groups [ Time Frame: 4 years ]Parkinson Disease Quotation (PDQ-39) quiz score [0-4 : higher scores mean worse outcome]
- Evolution of walking speed in both patient groups [ Time Frame: 4 years ]Right and left foot speed measured during a walking task on the Vicon platform without and with dopaminergic treatment
- Evolution of walking parameters in both patient groups [ Time Frame: 4 years ]Score in the "freezing of gait" questionnaire [0-24 : higher scores mean worse outcome] without and with dopaminergic treatment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04261569
|Contact: Cécile MORO, PhD||33 (0)4 38 78 06 firstname.lastname@example.org|
|Contact: Caroline SANDRE-BALLESTER, PhD||33 (0)4 38 78 28 51||CSandreballester@chu-grenoble.fr|
|Principal Investigator:||Stephan CHABARDES, MD, PhD||University Hospital, Grenoble|